Abstract
The scaffold protein Axin plays important roles in multiple signaling pathways through mediating the formation of different signaling complexes. Axin is best known for its role as a negative regulator in Wnt/β-catenin pathway. Aberrant activation of the key components in Wnt/β-catenin pathway including Axin has been linked to a variety of human cancers. Drugs developed for this pathway are far from satisfying largely due to the limited targets especially enzymesin this pathway. Almost all Axinsignal pathways depend on a number of protein-protein interactions (PPIs) for transmitting information, making PPIs attractive targets and probably a future direction for drug discovery. Axin interacts with a plethora of proteins, positively or negatively regulating several signaling pathways that are closely involved in the pathogenesis of human disease. Studies in recent years indicated Axin as a promising target for treating Wnt-driven diseases. With the identification of more interacting partners for Axin and increased understanding about the roles of these Axin-mediated PPIs in human disease, new targets may surface from the Axin PPI networks, which may lead to the generation of new drugs and treatmentstrategies. In this review, we outline the Axin PPI networks in several pathways especially in Wnt signaling and discuss how those Axin-interacting proteins affect the respective signaling pathways through an interaction with Axin.
Keywords: Axin, Signaling pathways, Protein-protein interactions, Drug target, Wnt/β-catenin pathway.
Current Topics in Medicinal Chemistry
Title:Axin PPI Networks: New Interacting Proteins and New Targets?
Volume: 16 Issue: 30
Author(s): Xiaomin Song, Wenwen Cai and Lin Li
Affiliation:
Keywords: Axin, Signaling pathways, Protein-protein interactions, Drug target, Wnt/β-catenin pathway.
Abstract: The scaffold protein Axin plays important roles in multiple signaling pathways through mediating the formation of different signaling complexes. Axin is best known for its role as a negative regulator in Wnt/β-catenin pathway. Aberrant activation of the key components in Wnt/β-catenin pathway including Axin has been linked to a variety of human cancers. Drugs developed for this pathway are far from satisfying largely due to the limited targets especially enzymesin this pathway. Almost all Axinsignal pathways depend on a number of protein-protein interactions (PPIs) for transmitting information, making PPIs attractive targets and probably a future direction for drug discovery. Axin interacts with a plethora of proteins, positively or negatively regulating several signaling pathways that are closely involved in the pathogenesis of human disease. Studies in recent years indicated Axin as a promising target for treating Wnt-driven diseases. With the identification of more interacting partners for Axin and increased understanding about the roles of these Axin-mediated PPIs in human disease, new targets may surface from the Axin PPI networks, which may lead to the generation of new drugs and treatmentstrategies. In this review, we outline the Axin PPI networks in several pathways especially in Wnt signaling and discuss how those Axin-interacting proteins affect the respective signaling pathways through an interaction with Axin.
Export Options
About this article
Cite this article as:
Song Xiaomin, Cai Wenwen and Li Lin, Axin PPI Networks: New Interacting Proteins and New Targets?, Current Topics in Medicinal Chemistry 2016; 16 (30) . https://dx.doi.org/10.2174/1568026616666160622220245
DOI https://dx.doi.org/10.2174/1568026616666160622220245 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Progress Toward Vector Design for Hematopoietic Stem Cell Gene Therapy
Current Gene Therapy Thioredoxin System Modulation by Plant and Fungal Secondary Metabolites
Current Medicinal Chemistry Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets Prevention and Treatment of Bone Metastases
Current Pharmaceutical Design MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews Chronic Myelogenous Leukemia
Current Cancer Therapy Reviews Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Current Cancer Therapy Reviews Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Targeting the Hedgehog Pathway: The development of Cyclopamine and the Development of Anti-Cancer Drugs Targeting the Hedgehog Pathway
Mini-Reviews in Medicinal Chemistry Selective Binding BAFF/APRIL by the In and Outside Conservative Region of BCMA
Protein & Peptide Letters RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Drug Repurposing for the Treatment of Staphylococcal Infections
Current Pharmaceutical Design Equilibrative Nucleoside (ENTs) and Cationic Amino Acid (CATs) Transporters: Implications in Foetal Endothelial Dysfunction in Human Pregnancy Diseases
Current Vascular Pharmacology